MX2016004445A - Stable triflusal powder formulation for oral administration and method of preparation thereof. - Google Patents
Stable triflusal powder formulation for oral administration and method of preparation thereof.Info
- Publication number
- MX2016004445A MX2016004445A MX2016004445A MX2016004445A MX2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A
- Authority
- MX
- Mexico
- Prior art keywords
- triflusal
- oral administration
- stable
- preparation
- powder formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
The present invention relates to a dispersible pharmaceutical formulation in the form of granules for oral administration comprising Triflusal together with at least one pharmaceutically acceptable excipient and a method for manufacturing thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/003039 WO2015051811A1 (en) | 2013-10-10 | 2013-10-10 | Stable triflusal powder formulation for oral administration and method of preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016004445A true MX2016004445A (en) | 2016-07-21 |
Family
ID=49474361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004445A MX2016004445A (en) | 2013-10-10 | 2013-10-10 | Stable triflusal powder formulation for oral administration and method of preparation thereof. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3054922A1 (en) |
KR (1) | KR20160067175A (en) |
MX (1) | MX2016004445A (en) |
WO (1) | WO2015051811A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011036533A1 (en) * | 2009-09-23 | 2011-03-31 | Glenmark Pharmaceuticals Limited | Pharmaceutical composition comprising prasugrel and triflusal |
ES2389348B1 (en) * | 2011-04-05 | 2013-09-23 | Simbec Ibérica Sl | TRIFLUSAL COMPOSITE POWDER, USE OF THE SAME FOR GRANULATES, COMPRESSED OR ENVELOPES, PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITE POWDER AND USE OF ONE OR MORE CYCLODEXTRINES TO STABILIZE THE TRIFLUSAL. |
-
2013
- 2013-10-10 WO PCT/EP2013/003039 patent/WO2015051811A1/en active Application Filing
- 2013-10-10 MX MX2016004445A patent/MX2016004445A/en unknown
- 2013-10-10 EP EP13780062.9A patent/EP3054922A1/en not_active Withdrawn
- 2013-10-10 KR KR1020167011991A patent/KR20160067175A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20160067175A (en) | 2016-06-13 |
EP3054922A1 (en) | 2016-08-17 |
WO2015051811A1 (en) | 2015-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000550A (en) | Tofacitinib oral sustained release dosage forms. | |
HK1223935A1 (en) | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration | |
HK1218884A1 (en) | Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity | |
MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
PL3003383T3 (en) | Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d | |
HK1200337A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
IL240666A0 (en) | Pharmaceutical compositions for oral delivery and uses thereof | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
IL239958A (en) | Chewable composition for oral administration and process for preparation thereof | |
WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
MX2014006201A (en) | Imatinib solid dosage forms reconstituted just before use. | |
MX2015015681A (en) | Pharmaceutical composition comprising fingolimod. | |
MX2016004445A (en) | Stable triflusal powder formulation for oral administration and method of preparation thereof. | |
EP3010534A4 (en) | Pharmaceutical formulations and methods for oral delivery of biologically active ingredient | |
EP2979698A4 (en) | Pharmaceutical composition for oral administration | |
MX2015013279A (en) | Tofacitinib oral sustained release dosage forms. | |
WO2013109213A3 (en) | Pharmaceutical formulations comprising tiotropium | |
PL2988782T3 (en) | Dosage forms for oral administration of active substances |